Melittin: a lytic peptide with anticancer properties

Environ Toxicol Pharmacol. 2013 Sep;36(2):697-705. doi: 10.1016/j.etap.2013.06.009. Epub 2013 Jun 28.

Abstract

Melittin (MEL) is a major peptide constituent of bee venom that has been proposed as one of the upcoming possibilities for anticancer therapy. Recent reports point to several mechanisms of MEL cytotoxicity in different types of cancer cells such as cell cycle alterations, effect on proliferation and/or growth inhibition, and induction of apoptotic and necrotic cell death trough several cancer cell death mechanisms, including the activation of caspases and matrix metalloproteinases. Although cytotoxic to a broad spectrum of tumour cells, the peptide is also toxic to normal cells. Therefore its therapeutic potential cannot be achieved without a proper delivery vehicle which could be overcome by MEL nanoparticles that possess the ability to safely deliver significant amount of MEL intravenously, and to target and kill tumours. This review paper summarizes the current knowledge and brings latest research findings on the anticancer potential of this lytic peptide with diverse functions.

Keywords: Anticancer effect; Apoptosis; Bee venom; Melittin; Necrosis; Tumour cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / isolation & purification
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / toxicity
  • Bee Venoms / chemistry*
  • Chemistry, Pharmaceutical
  • Drug Carriers
  • Humans
  • Melitten / chemistry
  • Melitten / isolation & purification
  • Melitten / pharmacology*
  • Melitten / toxicity
  • Nanoparticles

Substances

  • Antineoplastic Agents
  • Bee Venoms
  • Drug Carriers
  • Melitten